Ursodeoxycholic acid sodium 熊去氧胆酸钠盐; Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium,98.0%
产品编号:Bellancom-13771A| CAS NO:2898-95-5| 分子式:C24H39NaO4| 分子量:414.55
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
Ursodeoxycholic acid sodium 熊去氧胆酸钠盐; Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium
产品介绍 | Ursodeoxycholic acid (Ursodeoxycholate) sodium 是由肠道细菌转化 (cheno)脱氧胆酸而产生的一种次级胆汁酸,是肠道屏障完整性的关键调节因子,对脂质代谢至关重要。Ursodeoxycholic acid sodium 作为信号分子,通过与胆汁酸激活的受体相互作用发挥作用,包括G蛋白偶联的胆汁酸受体5 (TGR5,GPCR19) 和法尼酯X受体 (FXR)。Ursodeoxycholic acid sodium 可用于多种肝脏和胃肠道疾病的研究。具有口服活性。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active. | ||||||||||||||||
体外研究 | |||||||||||||||||
体内研究 |
Ursodeoxycholic acid (50, 150, and 450 mg/kg; p.o.; daily for 21 days) sodium results in weight loss in C57BL/6J wildtype mice. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
体内研究 |
Ursodeoxycholic acid (50, 150, and 450 mg/kg; p.o.; daily for 21 days) sodium results in weight loss in C57BL/6J wildtype mice. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 125 mg/mL (301.53 mM; ultrasonic and warming and heat to 60°C) H2O : ≥ 100 mg/mL (241.23 mM) * "≥" means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
参考文献 |
|